NCT03653117 is a NA clinical trial of Transperineal laser ablation in Prostatic Hyperplasia, Benign, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Who is sponsoring NCT03653117?

NCT03653117 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What drugs are being tested in NCT03653117?

Interventions in NCT03653117: Transperineal laser ablation.

What condition does NCT03653117 study?

NCT03653117 studies Prostatic Hyperplasia, Benign.

Is NCT03653117 still recruiting?

NCT03653117 is currently completed. Last updated 21 June 2022.

Last reviewed 2022-06-21 · How we verify

NCT03653117

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transperineal Laser Ablation for Treatment of Benign Prostatic Obstruction

Completed NA Last updated 21 June 2022

What this trial tests

NA trial testing Transperineal laser ablation in Prostatic Hyperplasia, Benign in 20 participants. Completed in 23 May 2022.

Timeline

18 October 2018

Primary endpoint
23 May 2022

23 May 2022

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	18 October 2018
Primary completion	23 May 2022
Estimated completion	23 May 2022
Sites	1 location across Netherlands

Drugs / interventions tested

Transperineal laser ablation

Conditions studied

Prostatic Hyperplasia, Benign — all drugs for Prostatic Hyperplasia, Benign →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

40 and older, male only, with Prostatic Hyperplasia, Benign. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: With age a large group of men experience lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO). Standard treatment is a transurethral resection of the prostate or laser vaporization. As these techniques enter the prostate via the urethra, are invasive and require general or spinal anaesthesia. Transperineal laser ablation (TPLA) is a minimal invasive procedure, that can be performed under local anaesthesia. Objective: The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men. Secondary objectives: The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Transperineal Laser Ablation for Benign Prostatic Enlargement: A Systematic Review and Pooled Analysis of Pilot Studies.
Tafuri A, Panunzio A, De Carlo F, Luperto E, et al · · 2023 · cited 12× · PMID 36902647 · DOI 10.3390/jcm12051860
Transperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes-A pilot study.
van Kollenburg R, van Riel L, Bloemen P, de Reijke T, et al · · 2024 · cited 5× · PMID 38179027 · DOI 10.1002/bco2.278

Verify or expand the search:

Other recruiting trials for Prostatic Hyperplasia, Benign

Currently open trials in the same condition.

NCT07417449 — Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP · recruiting

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03653117 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last refreshed: 21 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing